PTEN, a tumor suppressor regulating the PI3K-AKT pathway, is frequently lost in Middle Eastern breast cancers, particularly in triple-negative subtypes, and its inactivation is associated with aggressive tumor features and poor prognosis, highlighting its potential as a therapeutic target. This evidence concerns the gene PTEN and neoplasm.